Compare · DXCM vs INBS
DXCM vs INBS
Side-by-side comparison of DexCom Inc. (DXCM) and Intelligent Bio Solutions Inc. (INBS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and INBS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $40.07B.
- Over the past year, DXCM is down 13.5% and INBS is down 79.7% - DXCM leads by 66.2 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 2 for INBS).
- DXCM has more recent analyst coverage (25 ratings vs 0 for INBS).
- Company
- DexCom Inc.
- Intelligent Bio Solutions Inc.
- Price
- $61.55-1.84%
- $2.58-2.46%
- Market cap
- $40.07B
- -
- 1M return
- -7.89%
- -25.36%
- 1Y return
- -13.51%
- -79.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2020
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest INBS
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
- Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
- Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Intelligent Bio Solutions Inc.
- SEC Form 4 filed by Boyages Steven Constantine
- SEC Form 4 filed by Hurd Jonathan Scott
- SEC Form 4 filed by Sakiris Spiro Kevin
- SEC Form 4 filed by Isenberg Jason